Peptide Therapy, Guided by Science.
PEPTIDE MEDICINE
Peptide Therapy, Guided by Science.
Peptides are naturally occurring chains of amino acids that act as signalling molecules throughout the body, influencing a wide range of biological processes.
At Vilnius Vitality, peptide-based therapies are considered within a physician-led, diagnostics-first framework—with attention to clinical evidence, quality, safety and individual suitability.
Treatment availability and suitability are subject to physician assessment, clinical eligibility, product authorisation, applicable regulation and individual circumstances.
Understanding Peptides
What Are Peptides?
Peptides are short chains of amino acids—the same biological building blocks that form proteins.
Many peptides occur naturally in the human body and act as chemical messengers, helping cells and biological systems communicate with one another. Different peptides interact with different receptors and pathways, which means their functions can vary considerably.
The term “peptide” describes a type of molecule. It does not, by itself, establish that a product is effective, safe, authorised or suitable for medical use.
Each peptide-based intervention must be assessed according to:
Its specific identity and mechanism
The condition or objective being considered
The quality and relevance of the evidence
Its regulatory and authorisation status
Product quality and manufacturing controls
Potential benefits and limitations
Known and potential risks
Interactions and contraindications
Appropriate dosing and monitoring requirements
How Peptide Medicines Work
Small Molecules. Specific Biological Pathways.
Peptides can bind to receptors on or within cells and influence particular biological signals.
Depending on the specific peptide, these signals may relate to areas such as hormone regulation, glucose metabolism, appetite, digestion or other physiological processes.
However, peptides are not interchangeable. Evidence relating to one peptide, formulation or medical indication cannot automatically be applied to another.
A responsible medical assessment therefore begins with the individual product and its intended clinical use—not with general claims about “peptide therapy.”
Individualised Assessment
There Is No Universal Peptide Protocol
Two people with similar goals may have very different medical histories, biological profiles, risk factors and treatment needs.
For this reason, Vilnius Vitality does not begin with:
“Which peptide would you like?”
We begin with:
“What are we trying to understand, and what would be medically appropriate?”
Where treatment is considered, your physician should explain:
Why the specific intervention is being discussed
Whether it is authorised for the proposed indication
The strength and limitations of the available evidence
Potential benefits and realistic expectations
Known and potential adverse effects
Contraindications and possible interactions
Available alternatives, including no treatment
How the medicine would be administered
What monitoring and follow-up would be required
When treatment should be reviewed, adjusted or discontinued
Evidence and Regulatory Status
Not Every Peptide Has the Same Status
Some peptide-based medicines have been authorised for specific indications following regulatory assessment. Other peptides may be used only in research, remain under clinical investigation or have no authorisation for human treatment.
“Used by a clinic,” “available online” or “described in scientific research” does not necessarily mean that a product is authorised, proven effective or appropriate for an individual patient.
